Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy

30 Sept 2022

Abstract excerpt

ARID1A is frequently mutated in colorectal cancer (CRC) cells. Loss of ARID1A function compromises DNA damage repair and increases the reliance of tumor cells on ATR-dependent DNA repair pathways. Here, we investigated the effect of ionizing radiation (IR), in combination with ATR inhibitors (ATRi) in CRC cell lines with proficient and deficient ARID1A. The concept of selective vulnerability of ARID1A deficient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Chromatin Remodeling and Cancer
Share to Signaling Pathways in Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36249060
DOI: 10.3389/fonc.2022.999626

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapyPMID 36249060Read ↗

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1ASemantic proximity Read ↗

Targeting ARID1A-mutant colorectal cancer: depletion of ARID1B increases radiosensitivity and modulates DNA damage response.Semantic proximity Read ↗

CHK1 inhibition increases the therapeutic response to radiotherapy via antitumor immunity in ARID1A-deficient colorectal cancerSemantic proximity Read ↗

Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor TherapySemantic proximity Read ↗

Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R-Loop Accumulation and DNA Repair Deficiencies.Semantic proximity Read ↗

Leveraging a Patient-Derived Tumoroid Platform for Precision Radiotherapy: Uncovering DNA Damage Repair Inhibitor-Mediated Radiosensitization and Therapeutic Resistance in Rectal CancerSemantic proximity Read ↗

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP InhibitorsSemantic proximity Read ↗

ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer.Semantic proximity Read ↗

Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal CancerSemantic proximity Read ↗

ARID1A loss enhances sensitivity to c-MET inhibition by dual targeting of GPX4 and iron homeostasis, inducing ferroptosisSemantic proximity Read ↗

The DNA damage response to ATR inhibitionSemantic proximity Read ↗

Differential DNA damage response to WRN inhibition identifies a targetable vulnerability in ARID1A-mutated cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.